Cargando…

Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients

Successful allogeneic hematopoietic stem cell transplantation (HSCT) depends not only on good HLA match but also on T-cell mediated graft-versus-leukemia (GvL) effect. Natural killer (NK) cells are able to kill malignant cells by receiving activation signal from the killer-cell immunoglobulin-like r...

Descripción completa

Detalles Bibliográficos
Autores principales: Impola, Ulla, Turpeinen, Hannu, Alakulppi, Noora, Linjama, Tiina, Volin, Liisa, Niittyvuopio, Riitta, Partanen, Jukka, Koskela, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142321/
https://www.ncbi.nlm.nih.gov/pubmed/25202311
http://dx.doi.org/10.3389/fimmu.2014.00405
_version_ 1782331759281569792
author Impola, Ulla
Turpeinen, Hannu
Alakulppi, Noora
Linjama, Tiina
Volin, Liisa
Niittyvuopio, Riitta
Partanen, Jukka
Koskela, Satu
author_facet Impola, Ulla
Turpeinen, Hannu
Alakulppi, Noora
Linjama, Tiina
Volin, Liisa
Niittyvuopio, Riitta
Partanen, Jukka
Koskela, Satu
author_sort Impola, Ulla
collection PubMed
description Successful allogeneic hematopoietic stem cell transplantation (HSCT) depends not only on good HLA match but also on T-cell mediated graft-versus-leukemia (GvL) effect. Natural killer (NK) cells are able to kill malignant cells by receiving activation signal from the killer-cell immunoglobulin-like receptors (KIR) recognizing HLA molecules on a cancer cell. It has been recently reported that the risk of relapse in allogeneic hematopoietic stem cell transplantation (HSCT) is reduced in acute myeloid leukemia (AML) patients whose donors have several activating KIR genes or KIR B-motifs in unrelated donor setting, obviously due to enhanced GvL effect by NK cells. We studied the effect on relapse rate of donor KIR haplotypes in the HLA-identical adult sibling HSCT, done in a single center, in Helsinki University Central Hospital, Helsinki, Finland. Altogether, 134 patients with 6 different diagnoses were identified. Their donors were KIR genotyped using the Luminex and the SSP techniques. The clinical endpoint, that is, occurrence of relapse, was compared with the presence or absence of single KIR genes. Also, time from transplantation to relapse was analyzed. The patients with AML whose donors have KIR2DL2 or KIR2DS2 had statistically significantly longer relapse-free survival (P = 0.015). Our data support previous reports that donors with KIR B-haplotype defining genes have a lower occurrence of relapse in HSCT of AML patients. Determination of donor KIR haplotypes could be a useful addition for a risk assessment of HSCT especially in AML patients.
format Online
Article
Text
id pubmed-4142321
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-41423212014-09-08 Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients Impola, Ulla Turpeinen, Hannu Alakulppi, Noora Linjama, Tiina Volin, Liisa Niittyvuopio, Riitta Partanen, Jukka Koskela, Satu Front Immunol Immunology Successful allogeneic hematopoietic stem cell transplantation (HSCT) depends not only on good HLA match but also on T-cell mediated graft-versus-leukemia (GvL) effect. Natural killer (NK) cells are able to kill malignant cells by receiving activation signal from the killer-cell immunoglobulin-like receptors (KIR) recognizing HLA molecules on a cancer cell. It has been recently reported that the risk of relapse in allogeneic hematopoietic stem cell transplantation (HSCT) is reduced in acute myeloid leukemia (AML) patients whose donors have several activating KIR genes or KIR B-motifs in unrelated donor setting, obviously due to enhanced GvL effect by NK cells. We studied the effect on relapse rate of donor KIR haplotypes in the HLA-identical adult sibling HSCT, done in a single center, in Helsinki University Central Hospital, Helsinki, Finland. Altogether, 134 patients with 6 different diagnoses were identified. Their donors were KIR genotyped using the Luminex and the SSP techniques. The clinical endpoint, that is, occurrence of relapse, was compared with the presence or absence of single KIR genes. Also, time from transplantation to relapse was analyzed. The patients with AML whose donors have KIR2DL2 or KIR2DS2 had statistically significantly longer relapse-free survival (P = 0.015). Our data support previous reports that donors with KIR B-haplotype defining genes have a lower occurrence of relapse in HSCT of AML patients. Determination of donor KIR haplotypes could be a useful addition for a risk assessment of HSCT especially in AML patients. Frontiers Media S.A. 2014-08-25 /pmc/articles/PMC4142321/ /pubmed/25202311 http://dx.doi.org/10.3389/fimmu.2014.00405 Text en Copyright © 2014 Impola, Turpeinen, Alakulppi, Linjama, Volin, Niittyvuopio, Partanen and Koskela. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Impola, Ulla
Turpeinen, Hannu
Alakulppi, Noora
Linjama, Tiina
Volin, Liisa
Niittyvuopio, Riitta
Partanen, Jukka
Koskela, Satu
Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
title Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
title_full Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
title_fullStr Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
title_full_unstemmed Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
title_short Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
title_sort donor haplotype b of nk kir receptor reduces the relapse risk in hla-identical sibling hematopoietic stem cell transplantation of aml patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142321/
https://www.ncbi.nlm.nih.gov/pubmed/25202311
http://dx.doi.org/10.3389/fimmu.2014.00405
work_keys_str_mv AT impolaulla donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT turpeinenhannu donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT alakulppinoora donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT linjamatiina donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT volinliisa donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT niittyvuopioriitta donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT partanenjukka donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients
AT koskelasatu donorhaplotypebofnkkirreceptorreducestherelapseriskinhlaidenticalsiblinghematopoieticstemcelltransplantationofamlpatients